Project Grant R01DE033862

Award Date 9/1/24
Completion Date 5/31/29
Dollars Obligated $599K
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) provides $515,812 to The Johns Hopkins University to study the progression of HPV-related oropharynx cancer (HPV-OPC) and how it differs between individuals with and without HIV. The study aims to: 1) characterize the impact of HIV on oral HPV16 persistence, 2) evaluate the performance of oral and blood biomarkers for...
This federal Project Grant award of $2,740,126, provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to investigate the mechanisms by which HIV infection contributes to the development of oropharyngeal cancer (OPC) in people living with HIV (PWH). The key objectives are to: 1) Determine the HPV types present in OPC from PWH and how T cell-mediated anti-tumor immunity is impaired;...
This federal Project Grant award of $492,000 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, will fund a pilot study to evaluate the feasibility and acceptability of using mail-delivered sample collection kits to detect oral human papillomavirus (HPV) infection among a racially/ethnically diverse population of sexual minority men living with HIV. The study aims to assess the agreement between at-home...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will fund research to investigate the role of antiretroviral therapy (ART) on susceptibility to oral human papillomavirus (HPV) infection. The $1,913,543 award to Louisiana State University Health Sciences Center New Orleans will support three specific aims: 1) comparing the prevalence and incidence of oral HPV infection...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $315,000 to the University of California, Los Angeles (UCLA) to conduct a longitudinal study on the oral microbiome of HIV-exposed uninfected (HEU), HIV-positive, and HIV-unexposed uninfected children aged 3-4 in Western Kenya. The study will collect and analyze 1,080 oral swab samples over one year to understand how...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $451,000.00 to the University of Chicago to conduct research aimed at deciphering the mechanisms behind patient responses to a novel immunotherapy targeting human papillomavirus (HPV) associated head and neck cancer. The key objectives of this 2-year research project are to leverage patient tumor biopsies, plasma samples,...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a Project Grant (CFDA 93.121 - Oral Diseases and Disorders Research) to the University of Arizona in the amount of $118,763 for the period of September 1, 2024 to August 31, 2026. The grant will support Dr. Robert Jackson's research focused on assessing the role of human papillomavirus type 16 (HPV16) in transforming versus productive infections in oral epithelial tissues. The research aims to characterize the viral...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $315,000 to The Ohio State University to develop novel antibody therapeutics targeting the human papillomavirus (HPV) oncoproteins E6 and E7. The goal is to leverage the university's unique platform of HPV-specific human monoclonal antibodies to generate dimeric IgA molecules that can efficiently inhibit the growth of...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $642,488 to a collaborative research partnership between Henry Ford Health and Michigan State University Health Sciences. The funding will support a 5-year research project focused on understanding the mechanisms by which human papillomavirus (HPV) promotes immune evasion in head and neck squamous cell carcinomas (HNSCC)....
This Cooperative Agreement award of $638,903, funded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research (CFDA 93.121) program, aims to validate a novel prognostic biomarker that captures tumor biology and heterogeneity in over 1,000 diverse human papillomavirus positive (HPV+) oropharyngeal cancer (OPC) patients. The goal is to guide clinical decision-making and reduce treatment-related toxicity and morbidity. Key products and...

This $598,940 federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) aims to characterize the longitudinal events of oral high-risk human papillomavirus (OHR-HPV) infection among an at-risk population of non-heterosexual males living with or without HIV in Nigeria.

The primary objectives are to: 1) determine the association between HIV clinical markers, oral-anogenital contact, and the prevalence of OHR-HPV; 2) compare the time course of OHR-HPV as a function of HIV status; and 3) evaluate the relationship between dental phenotypes, the oral microbiome, HIV clinical measures, and OHR-HPV infection. The project will leverage an established cohort at the Trust Clinic in Nigeria and follow 500 participants over 2 years, collecting oral, blood, and clinical data to better understand the natural history of OHR-HPV and its link to HIV, the oral microbiome, and oral health indicators. This research aims to inform predictive models and risk-stratified screening approaches to mitigate the risk of HPV-related oropharyngeal cancer in males living with HIV.

The University of Maryland, Baltimore is the prime awardee, with sub-awards to the Institute of Human Virology Nigeria and the University of Pennsylvania to support the study's implementation in Nigeria and provision of specialized research services, respectively.

Generated 7/1/25, 3:03 AM